The purpose of this study is to determine the safety and effectiveness of BIO 300 Oral
Suspension when used in combination with standard dose radiation therapy and chemotherapy in
patients with non-small cell lung cancer. Based on preclinical data the investigators
hypothesize that BIO 300 Oral Suspension will reduce the incidence of radiation-induced
pneumonitis and pulmonary fibrosis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Humanetics Corporation
Collaborators:
Henry Ford Health System Medical College of Wisconsin Milwaukee VA Medical Center National Cancer Institute (NCI) University of Maryland, Baltimore